Abstract. Endothelial dysfunction is associated with pathological vascular conditions including atherosclerosis, hypertension, and diabetes. The oxidatively modified form of low-density lipoprotein (LDL) is recognized as a major cause of endothelial dysfunction in atherogenesis. As the receptor for oxidized LDL in endothelial cells, we have identified the lectin-like oxidized LDL receptor-1 (LOX-1). LOX-1 is up-regulated by products of oxidative stresses and the molecules that induce oxidative stresses. Activation of LOX-1 induces the generation of reactive oxygen species and decreases NO released from endothelial cells. LOX-1 activation further induces the expression of endothelin-1, AT 1 receptor, and cell adhesion molecules. Together with these properties, LOX-1 works as an adhesion molecule for activated platelets and neutrophils. Thus, LOX-1, within the close relationships between oxidative stress generation and response, enhances functional changes in endothelial cells that are relevant to the disturbed vascular homeostasis under pathological settings.
Atherosclerosis is a multifactorial disease in which the cellular and molecular mechanisms contributing to the disease process are not defined well. Atherosclerosis is generally viewed as a chronic inflammatory disease of the arterial intima characterized by the formation of the atherosclerotic plaque, which is a focal accumulation of mononuclear leukocytes, smooth muscle cells, lipids, and extracellular matrix components. In the normal, healthy state, the vessel wall is composed of a singlecell-thick endothelial cell-lining that exhibits intimate contact with the medical layer of vascular smooth muscle cells. Encircling this is the layer consisting of a dense matrix of connective tissue. As such, the endothelial cell is situated at the interface between the circulating blood and vessel wall to serve as a sensor and transducer of signals within the circulatory microenvironment. Therefore, the endothelial cell is integral in maintaining the homeostatic balance of the vessel through the production of factors that regulate vessel tone, coagulation state, cellular proliferative response, and leukocyte trafficking. However, in a primary lesion of atherosclerosis, endothelial dysfunction occurs when the cell loses its ability to maintain the normal homeostatic balance, leading to impairment in vasorelaxation and increased adhesiveness of the endothelial cell lining for circulating inflammatory cells (1) . That is to say, endothelial dysfunction includes the impairment of endothelial NO formation and the induction of the expression of adhesion molecules and smooth muscle growth factors.
The endothelial receptor for oxidized low-density lipoprotein: LOX-1
The oxidatively modified form of low-density lipoprotein (LDL) is implicated in the pathogenesis of atherosclerosis. Oxidized LDL, through a various classes of scavenger receptors, such as SR-AI / II, CD36, and macrosialin / CD68, is taken up by macrophages and smooth muscle cells (2, 3) . The phagocytosis of oxidized LDL changes the macrophages and smooth muscle cells into foam cells, which are a hallmark of atheroma. On the other hand, it had been known that endothelial cells internalize and degrade the oxidized LDL by the putative endothelial cell-surface receptor (4 -6) . This is thought to be a major cause of endothelial dysfunction. In 1997, Sawamura et al. initially identified cDNA encoding an endothelial receptor for oxidized LDL, which was designated as lectin-like oxidized LDL receptor-1, LOX-1 (7, 8) . LOX-1 is a type-II membrane protein that belongs to a family of C-type lectin-like molecules.
Oxidative stresses induce LOX-1 expression LOX-1 expression in endothelial cells is relatively lower in the basal condition, but it can be induced by proinflammatory cytokines and vasoconstrictive peptides in vitro (9 -15) ; and in proatherogenic conditions in vivo such as hypertention (16) , diabetes (17) , and hyperlipidemia (18) .
Interestingly, LOX-1 expression is upregulated by its ligand, oxidized LDL, in cultured endothelial cells (19, 20) . In contrast to oxidized LDL, native LDL had no effects on the expression of LOX-1 (19) . The upregulation by oxidized LDL is inhibited by anti-LOX-1 antibody. These results suggest that LOX-1 is upregulated by the binding of oxidized LDL to LOX-1, which would further enhance the uptake of oxidized LDL and endothelial activation and dysfunction.
Oxidized LDL is recognized as a product made by the exposure of LDL to oxidative stress. It is reported that some other molecules related to oxidative stress also induce LOX-1 expression. Isoprostanes are prostaglandin isomers formed by free radical peroxidation of arachidonic acid present in phospholipids. Among these isoprostanes, 8-iso-prostaglandin F 2a is well known as a marker of oxidative stress. Halvorsen et al. demonstrated that uptake of oxidized LDL and expression of LOX-1 were increased by 8-iso-prostaglandin F 2a in JAR cells. In addition, they showed that 8-iso-prostaglandin F 2a induced NF-kB activation, which is a redox sensitive transcription factor (21) . Besides the products of oxidative stress, the molecules that induce oxidative stress are known to induce LOX-1 expression. Homocysteine, an atherogenic factor, is believed to exert its effects through oxidative stress. Homocysteine is readily oxidized when added to plasma, principally as a consequence of auto-oxidation leading to the formation of homocystine, homocysteinemixed disulfides, and homocysteine thiolactone. During oxidation of the sulfhydryl group, superoxide anion radical and hydrogen peroxide are generated. Nagase et al. demonstrated that homocysteine enhanced LOX-1 expression and this enhancement is suppressed by Nacetylcysteine (23) .
Another example of redox sensitive regulation of LOX-1 expression is the induction by angiotensin II. LOX-1 was upregulated by angiotensin II in cultured human coronary artery endothelial cells. This upregulation of LOX-1 was blocked by pretreatment with losartan, a specific AT 1 blocker, but not by PD123319, a specific AT 2 blocker (13). Angiotensin II has been reported to generate superoxide anions through the activation of NADH / NADPH oxidase in aortas of angiotensin II-induced hypertensive rats. To explore the involvement of reactive oxygen species (ROS) in upregulation of LOX-1 expression, Nagase et al. utilized angiotensin II-induced hypertensive rats. While LOX-1 mRNA level was very low in the aorta of sham operated rats, it was markedly augmented in that of angiotensin II-induced hypertensive rats. This increase in LOX-1 expression was completely inhibited by an AT 1 -receptor antagonist, and attenuated by a SOD mimetic antioxidant, Tempo (23) . These results indicate that redoxsensitive regulation of LOX-1 actually occurs in vivo.
In vivo, LOX-1 expression upregulated in several pathological settings including hypertension (16), hyperlipidemia (18), diabetes (17) , and even atherosclerosis per se (24) . In these pathological settings, the high levels of ROS in vasculature might be an underlying mechanism for the up-regulation of LOX-1 in these conditions.
Activation of LOX-1 induces oxidative stress and endothelial dysfunction
The induced expression of LOX-1 in endothelial cells upon various pathologic stimuli would provide a molecular link for incorporation of oxidized LDL into the cells, resultant cellular activation, dysfunction, and injury. Since oxidized LDL has been shown to generate reactive oxygen intermediates, tethering oxidized LDL via LOX-1 would focus oxidant stress on cellular targets, resulting in changes in gene expression and the cellular phenotype and in some cases inducing apoptosis.
Recent studies by Cominacini et al. convincingly showed oxidized LDL binding to LOX-1 in endothelial cells induces the generation of superoxide anion and activates NF-kB (25) . As DPI, a selective inhibitor of NADPH oxidase, drastically reduced intracellular superoxide concentration, oxidized LDL-induced superoxide generation might be related to the increased activity of NADPH oxidase.
The increased intracellular superoxide anion accelerates inactivation of NO (26) . Oxidized LDL decreases intracellular NO concentration in both basal and stimulated conditions by bradykinin and thrombin.
In addition, Li et al. showed that in human coronary artery endothelial cells, oxidized LDL decreases phosphorylation (activity) of PKB / Akt and downregulates eNOS activity (27) . These findings suggest that activation of LOX-1 decreases the release of NO not only by enhancing catabolism of NO but also by attenuating eNOS activity.
Since ROS function as signal transduction molecules that modulate the activity of the transcription factors, various changes via gene expression accompanies the changes in redox state of cells. Activation of NF-k B, a redox-sensitive transcription factor, induces upregulation in the expression of vasoconstrictive molecules, adhesion molecules, and chemokines (28, 29) . Actually, activation of LOX-1 in endothelial cells induces the expression of endothelin-1, AT 1 receptor, E-selectin, P-selectins, VCAM-1 and ICAM-1 (30) , and MCP-1 (31) . These gene products increase vascular tonus and promote the infiltration of monocytes into the vessel wall and the release of additional proinflammatory signals (Fig. 1) .
LOX-1 directly promotes endothelial dysfunction via cell-adhesion property
Besides oxidized LDL and AGE, platelets and leukocytes can also be recognized by LOX-1. The binding of platelets was inhibited by a phosphatidylserine-binding protein, annexin V, and enhanced by agonists for platelets. Therefore, the anionic phospholipids exposed on activation on the surface of platelets should be the epitopes for LOX-1. Notably, the binding of platelets to LOX-1 enhanced the release of endothelin-1 from endothelial cells, supporting the induction of endothelial activation. LOX-1-directed platelet-endothelium communication induces the phenotypic changes of endothelial cells (32) .
In a model of low dose endotoxin-induced uveitis, anti-LOX-1 antibody efficiently suppressed leukocyte infiltration and protein exudation. In situ videomicroscopic analyses of leukocyte interactions with retinal veins revealed that anti-LOX-1 antibody reduced the number of rolling leukocytes and increased the velocity of rolling, suggesting that LOX-1 functions as a vascular tethering ligand. The ability of LOX-1 to capture leukocytes under physiologic shear was confirmed in an in vitro flow model. Thus, LOX-1 is a novel adhesion molecule involved in leukocyte recruitment, and inflammation (33) .
These properties of LOX-1 itself can be understood to change endothelial functions, which increase prothrombotic and proinflammatory activity (Fig. 2) . Oxidative stress is also increased by the ROS from leukocytes infiltrated via LOX-1 together with superoxide produced in endothelial cells on the binding of LOX-1-ligands.
Concluding remarks
Thus, LOX-1 is involved in the synergistic interaction between the oxidative stress-induced response and the oxidative stress-producing process. The combination of prothrombotic and proinflammatory nature of LOX-1 itself in addition to the close relationship to oxidative stress suggests the potential importance of LOX-1 in cardiovascular disease. Analyses of genetic engineered animals and cardiovascular patients would further define the role for LOX-1 in the diseases.
